[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-338463-105":59,"doc-detail-338463-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","factors-influencing-immunotherapy-outcomes-in-cancer-sarcopenia-and-systemic-inflammation","Factors Influencing Immunotherapy Outcomes in Cancer - Sarcopenia and Systemic Inflammation","","Immunotherapy benefits many metastatic cancer patients, yet frailty and impaired immune function can limit treatment effectiveness. This retrospective study evaluates how sarcopenia, systemic inflammation, and Eastern Cooperative Oncology Group Performance Status (ECOG PS) relate to responses to immune checkpoint inhibitors. Data from 100 patients treated between 2015 and 2021 were analyzed using abdominal CT measurements and blood inflammatory markers, assessing overall survival and progression-free survival via univariable and multivariable models.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/factors-influencing-immunotherapy-outcomes-in-cancer-sarcopenia-and-systemic-inflammation/338463/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/factors-influencing-immunotherapy-outcomes-in-cancer-sarcopenia-and-systemic-inflammation/338463.png","ImageObject",300,407,{"name":92,"@type":93},"Seraphina","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-31","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the study’s primary objective?","Question",{"text":112,"@type":113},"To investigate how sarcopenia, systemic inflammation, and ECOG performance status influence the response to immunotherapy.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were sarcopenia and systemic inflammation assessed?",{"text":117,"@type":113},"Sarcopenia was diagnosed using abdominal computed tomography with gender-specific thresholds, while systemic inflammation was evaluated using markers such as CRP, NLR, PLR, albumin, and lactate dehydrogenase (LDH).",{"name":119,"@type":110,"acceptedAnswer":120},"Which findings relate sarcopenia to cancer outcomes?",{"text":121,"@type":113},"Sarcopenia was associated with worse progression-free survival, and hypoalbuminemia was identified as a significant prognostic factor for overall survival.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},338463,1790212132,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":44,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},962075114101,"https://ap-avatar.wpscdn.com/avatar/e000253a75eb197efd?x-image-process=image/resize,m_fixed,w_180,h_180&k=1780044092746381165","| Factors Inﬂuencing Immunotherapy Outcomes in Cancer: Sarcopenia and Systemic Inﬂammation | Cancer Control Volume 31: 1–9\u003Cbr>© The Author(s) 2024\u003Cbr>Article reuse guidelines:\u003Cbr>[sagepub.com/journals-permissions](sagepub.com/journals-permissions)\u003Cbr>[DOI: 10.1177/10732748241302248](DOI: 10.1177/10732748241302248)[ ](DOI: 10.1177/10732748241302248)[journals.sagepub.com/home/ccx](journals.sagepub.com/home/ccx)\u003Cbr>\u003Cbr>|\n| --- | --- |\n| Enes Ucgul, MD 1 􀀁, Deniz Can Guven, MD2, Aybala Nur Ucgul, MD3, Yakup Ozbay, MD4, Mehmet Ruhi Onur, MD4, and Serkan Akin, MD5\u003Cbr>Abstract\u003Cbr>Background: Immunotherapy has shown promise in treating various subtypes of metastatic cancers, but many patients are frail and may have compromised immune systems, which can inﬂuence treatment outcomes. Sarcopenia, a condition characterized by loss of muscle mass and systemic inﬂammation, is a potential factor that may negatively impact the response to immunotherapy. However, more data must be collected on the extent of its inﬂuence. Therefore, this study aims to investigate the effects of sarcopenia, systemic inﬂammation, and Eastern Cooperative Oncology Group Performance Status (ECOG PS) on the response to immunotherapy.\u003Cbr>Methods: We enrolled 100 patients treated with immune checkpoint inhibitors between 2015 and 2021 who underwent computed tomography of the abdomen before the ﬁrst immunotherapy dose. This study was conducted retrospectively. Gender-speciﬁc thresholds were used for the diagnosis of sarcopenia. C-reactive protein (CRP), erythrocyte sedimentation rate, neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), albumin, and lactate dehydrogenase (LDH) were used as markers of systemic inﬂammation. Systemic inﬂammatory markers and sarcopenia were assessed using univariable and multivariable analyses for overall survival (OS) and progression-free survival (PFS).\u003Cbr>Results: Sarcopenia was found to be a signiﬁcant prognostic factor associated with poor PFS (HR, 2.33; 95% conﬁdence interval [CI], 1.45-3.74; P \u003C 0.001). In addition, hypoalbuminemia was identiﬁed as a signiﬁcant prognostic factor for predicting OS (HR, 2.10; 95% CI, 1.21-3.66; P = 0.008).\u003Cbr>Conclusions: Closer monitoring and prevention of sarcopenia may enhance both OS and PFS. Additionally, our composite model may assist oncologists in predicting responses to immunotherapy more accurately. However, further prospective studies are needed to validate these ﬁndings.\u003Cbr>Plain Language Summary\u003Cbr>Background This study examines how muscle loss (sarcopenia), body inﬂammation, and overall health status affect patients’responses to cancer treatment with immunotherapy. Methods We studied 100 patients who received immunotherapy between 2015 and 2021 . Before starting treatment, these patients had an abdominal scan to check for muscle loss. We also measured several inﬂammatory markers in their blood, such as CRP and NLR. We analyzed how muscle loss and these inﬂammatory |  |\n| 1 Division of Endocrinology and Metabolism, Etlik City Hospital, Ankara, Turkey 2Department of Medical Oncology, Elazı˘g Fethi Sekin City Hospital, Elazı˘g, Turkey 3Department of Radiation Oncology, Gulhane Training and Research Hospital, Ankara, Turkey 4Department of Radiology, Hacettepe University Faculty of Medicine, Ankara, Turkey 5Department of Medical Oncology, Hacettepe University Cancer Institute, Ankara, Turkey\u003Cbr>Corresponding Author:\u003Cbr>Enes ¨Uçgül, Division of Endocrinology and Metabolism, Etlik City Hospital, Varlık Mahallesi, Halil Sezai Erkut, Ankara, Turkey.\u003Cbr>Email: [enes-ucgul@hotmail.com](enes-ucgul@hotmail.com) |  |\n\nCreative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons  \nAttribution-NonCommercial 4.0 License ([https://creativecommons.org/licenses/by-nc/4.0/](https://creativecommons.org/licenses/by-nc/4.0/)) which permits non-commercial use,  \nreproduction and distribution of the work without further permission provided the or","cbCaifMeXIXM46gI","https://ap.wps.com/l/cbCaifMeXIXM46gI","pdf",717091,"English","# Abstract\n# Methods\n# Results\n# Conclusions\n# Plain Language Summary\n# Keywords\n# Introduction","[{\"question\":\"What was the study’s primary objective?\",\"answer\":\"To investigate how sarcopenia, systemic inflammation, and ECOG performance status influence the response to immunotherapy.\"},{\"question\":\"How were sarcopenia and systemic inflammation assessed?\",\"answer\":\"Sarcopenia was diagnosed using abdominal computed tomography with gender-specific thresholds, while systemic inflammation was evaluated using markers such as CRP, NLR, PLR, albumin, and lactate dehydrogenase (LDH).\"},{\"question\":\"Which findings relate sarcopenia to cancer outcomes?\",\"answer\":\"Sarcopenia was associated with worse progression-free survival, and hypoalbuminemia was identified as a significant prognostic factor for overall survival.\"}]","Factors Influencing Immunotherapy Outcomes in Cancer - Sarcopenia and Systemic Inflammation | PDF",1790023727,23,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ad4090c9a513b1e414cc6f635319e2b7.webp",983,1272,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d935ee17404b7ca57b8dafb5a528b562.webp",982,1270,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0c6350d08a0cfcd0c50e8ab7be507ff4.webp",981,1269,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fbdcbc9065356c2cd3a682ab2f10996a.webp",980,1268]